隐蔽性生物瓣膜心内膜炎的晚期后果:诊断和治疗选择。

IF 0.6 Q4 SURGERY
Dominika Katarzyńska, Anna Olasińska-Wiśniewska, Marcin Misterski, Marek Grygier, Mateusz Puślecki, Sebastian Stefaniak, Tomasz Urbanowicz, Bartłomiej Perek, Marek Jemielity
{"title":"隐蔽性生物瓣膜心内膜炎的晚期后果:诊断和治疗选择。","authors":"Dominika Katarzyńska, Anna Olasińska-Wiśniewska, Marcin Misterski, Marek Grygier, Mateusz Puślecki, Sebastian Stefaniak, Tomasz Urbanowicz, Bartłomiej Perek, Marek Jemielity","doi":"10.5114/kitp.2023.129549","DOIUrl":null,"url":null,"abstract":"Address for correspondence: Dominika Katarzyńska MD, University Clinical Hospital, Poznan, Poland, e-mail: dominika.katarzynska@gmail.com Received: 12.05.2023, accepted: 25.06.2023. A 77-year-old male patient presented with heart failure symptoms (NYHA class III), which developed after probable infective endocarditis (IE) a few months earlier. Physical examination revealed new heart murmur and peripheral oedema. His other medical history includes hypertension, laryngeal tumor, and spine surgery. Nine years prior to this presentation, he was qualified for surgical aortic valve replacement (SAVR) due to a symptomatic severe aortic stenosis with mild aortic regurgitation. After sternotomy, he was deferred from prosthesis implantation as the porcelain aorta was revealed. Subsequently, he underwent successful transcatheter aortic valve implantation (TAVI) with Medtronic CoreValve 29 mm (Medtronic, Minneapolis, MN, USA) bioprosthesis. Postprocedural transthoracic echocardiography (TTE) showed proper bioprosthesis function with maximal transaortic gradient of 25 mm Hg without a paravalvular leak (PVL). The postoperative course was uneventful and on the 7th day he was discharged home. Three weeks after the procedure, the patient developed recurrent syncope, dizziness and chest pain. Electrocardiogram showed severe bradycardia with periodic third-degree atrioventricular block. A dual chamber pacemaker (BiotronicEcuro DR, Biotronik, Berlin, Germany) was implanted. During next 9 years the patient remained in a good clinical condition, though he underwent successful treatment of laryngeal tumor. The repeated echocardiographic examination confirmed proper bioprosthesis function. Six months before current hospitalization he presented with infection which was interpreted as pneumonia and treated successfully with antibiotics. Nevertheless, thereafter symptoms of heart failure occurred and gradually exacerbated. During the hospitalization due to heart failure worsening, TTE revealed hemodynamically severe intraprosthetic aortic regurgitation which had not been observed before (confirmed in transesophageal echocardiography (TEE) (Figure 1)) with transaortic maximal and mean gradients of 21 and 10 mm Hg, respectively, preserved left ventricular ejection fraction, and increased pulmonary artery systolic pressure. Laboratory tests did not present significant deviations in inflammatory markers and blood cultures were negative. After careful assessment by the heart team the patient was qualified for valve-in-valve TAVI (ViV-TAVI) due to a high perioperative risk and porcelain aorta. After careful assessment of computed tomography, he underwent successful uncomplicated implantation of Edwards Sapien (Edwards Lifesciences Corp., Irvine, CA, USA) prosthesis, which was chosen based on its optimal profile not limiting access to the coronary ostia. During follow-up he remains asymptomatic with good prosthesis function on control echocardiography. IE post-TAVI is not a common but serious complication with high in-hospital mortality, which is estimated at about 11–64% and 1-year mortality of 22–75% [1]. The overall incidence of IE post-TAVI is about 1% to 6% [2]. The rate of IE post-TAVI 1 year after surgery ranges from 0.5% to 3.1% and will increase as the procedure gains popularity and the operated patients are older and with a high Late consequences of masked bioprosthetic valve endocarditis: diagnostic and treatment options","PeriodicalId":49945,"journal":{"name":"Kardiochirurgia I Torakochirurgia Polska","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/25/KITP-20-51121.PMC10410635.pdf","citationCount":"0","resultStr":"{\"title\":\"Late consequences of masked bioprosthetic valve endocarditis: diagnostic and treatment options.\",\"authors\":\"Dominika Katarzyńska, Anna Olasińska-Wiśniewska, Marcin Misterski, Marek Grygier, Mateusz Puślecki, Sebastian Stefaniak, Tomasz Urbanowicz, Bartłomiej Perek, Marek Jemielity\",\"doi\":\"10.5114/kitp.2023.129549\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Address for correspondence: Dominika Katarzyńska MD, University Clinical Hospital, Poznan, Poland, e-mail: dominika.katarzynska@gmail.com Received: 12.05.2023, accepted: 25.06.2023. A 77-year-old male patient presented with heart failure symptoms (NYHA class III), which developed after probable infective endocarditis (IE) a few months earlier. Physical examination revealed new heart murmur and peripheral oedema. His other medical history includes hypertension, laryngeal tumor, and spine surgery. Nine years prior to this presentation, he was qualified for surgical aortic valve replacement (SAVR) due to a symptomatic severe aortic stenosis with mild aortic regurgitation. After sternotomy, he was deferred from prosthesis implantation as the porcelain aorta was revealed. Subsequently, he underwent successful transcatheter aortic valve implantation (TAVI) with Medtronic CoreValve 29 mm (Medtronic, Minneapolis, MN, USA) bioprosthesis. Postprocedural transthoracic echocardiography (TTE) showed proper bioprosthesis function with maximal transaortic gradient of 25 mm Hg without a paravalvular leak (PVL). The postoperative course was uneventful and on the 7th day he was discharged home. Three weeks after the procedure, the patient developed recurrent syncope, dizziness and chest pain. Electrocardiogram showed severe bradycardia with periodic third-degree atrioventricular block. A dual chamber pacemaker (BiotronicEcuro DR, Biotronik, Berlin, Germany) was implanted. During next 9 years the patient remained in a good clinical condition, though he underwent successful treatment of laryngeal tumor. The repeated echocardiographic examination confirmed proper bioprosthesis function. Six months before current hospitalization he presented with infection which was interpreted as pneumonia and treated successfully with antibiotics. Nevertheless, thereafter symptoms of heart failure occurred and gradually exacerbated. During the hospitalization due to heart failure worsening, TTE revealed hemodynamically severe intraprosthetic aortic regurgitation which had not been observed before (confirmed in transesophageal echocardiography (TEE) (Figure 1)) with transaortic maximal and mean gradients of 21 and 10 mm Hg, respectively, preserved left ventricular ejection fraction, and increased pulmonary artery systolic pressure. Laboratory tests did not present significant deviations in inflammatory markers and blood cultures were negative. After careful assessment by the heart team the patient was qualified for valve-in-valve TAVI (ViV-TAVI) due to a high perioperative risk and porcelain aorta. After careful assessment of computed tomography, he underwent successful uncomplicated implantation of Edwards Sapien (Edwards Lifesciences Corp., Irvine, CA, USA) prosthesis, which was chosen based on its optimal profile not limiting access to the coronary ostia. During follow-up he remains asymptomatic with good prosthesis function on control echocardiography. IE post-TAVI is not a common but serious complication with high in-hospital mortality, which is estimated at about 11–64% and 1-year mortality of 22–75% [1]. The overall incidence of IE post-TAVI is about 1% to 6% [2]. The rate of IE post-TAVI 1 year after surgery ranges from 0.5% to 3.1% and will increase as the procedure gains popularity and the operated patients are older and with a high Late consequences of masked bioprosthetic valve endocarditis: diagnostic and treatment options\",\"PeriodicalId\":49945,\"journal\":{\"name\":\"Kardiochirurgia I Torakochirurgia Polska\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/25/KITP-20-51121.PMC10410635.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kardiochirurgia I Torakochirurgia Polska\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/kitp.2023.129549\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kardiochirurgia I Torakochirurgia Polska","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/kitp.2023.129549","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。

Late consequences of masked bioprosthetic valve endocarditis: diagnostic and treatment options.

Late consequences of masked bioprosthetic valve endocarditis: diagnostic and treatment options.
Address for correspondence: Dominika Katarzyńska MD, University Clinical Hospital, Poznan, Poland, e-mail: dominika.katarzynska@gmail.com Received: 12.05.2023, accepted: 25.06.2023. A 77-year-old male patient presented with heart failure symptoms (NYHA class III), which developed after probable infective endocarditis (IE) a few months earlier. Physical examination revealed new heart murmur and peripheral oedema. His other medical history includes hypertension, laryngeal tumor, and spine surgery. Nine years prior to this presentation, he was qualified for surgical aortic valve replacement (SAVR) due to a symptomatic severe aortic stenosis with mild aortic regurgitation. After sternotomy, he was deferred from prosthesis implantation as the porcelain aorta was revealed. Subsequently, he underwent successful transcatheter aortic valve implantation (TAVI) with Medtronic CoreValve 29 mm (Medtronic, Minneapolis, MN, USA) bioprosthesis. Postprocedural transthoracic echocardiography (TTE) showed proper bioprosthesis function with maximal transaortic gradient of 25 mm Hg without a paravalvular leak (PVL). The postoperative course was uneventful and on the 7th day he was discharged home. Three weeks after the procedure, the patient developed recurrent syncope, dizziness and chest pain. Electrocardiogram showed severe bradycardia with periodic third-degree atrioventricular block. A dual chamber pacemaker (BiotronicEcuro DR, Biotronik, Berlin, Germany) was implanted. During next 9 years the patient remained in a good clinical condition, though he underwent successful treatment of laryngeal tumor. The repeated echocardiographic examination confirmed proper bioprosthesis function. Six months before current hospitalization he presented with infection which was interpreted as pneumonia and treated successfully with antibiotics. Nevertheless, thereafter symptoms of heart failure occurred and gradually exacerbated. During the hospitalization due to heart failure worsening, TTE revealed hemodynamically severe intraprosthetic aortic regurgitation which had not been observed before (confirmed in transesophageal echocardiography (TEE) (Figure 1)) with transaortic maximal and mean gradients of 21 and 10 mm Hg, respectively, preserved left ventricular ejection fraction, and increased pulmonary artery systolic pressure. Laboratory tests did not present significant deviations in inflammatory markers and blood cultures were negative. After careful assessment by the heart team the patient was qualified for valve-in-valve TAVI (ViV-TAVI) due to a high perioperative risk and porcelain aorta. After careful assessment of computed tomography, he underwent successful uncomplicated implantation of Edwards Sapien (Edwards Lifesciences Corp., Irvine, CA, USA) prosthesis, which was chosen based on its optimal profile not limiting access to the coronary ostia. During follow-up he remains asymptomatic with good prosthesis function on control echocardiography. IE post-TAVI is not a common but serious complication with high in-hospital mortality, which is estimated at about 11–64% and 1-year mortality of 22–75% [1]. The overall incidence of IE post-TAVI is about 1% to 6% [2]. The rate of IE post-TAVI 1 year after surgery ranges from 0.5% to 3.1% and will increase as the procedure gains popularity and the operated patients are older and with a high Late consequences of masked bioprosthetic valve endocarditis: diagnostic and treatment options
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.90
自引率
14.30%
发文量
44
审稿时长
6-12 weeks
期刊介绍: Polish Journal of Thoracic and Cardiovascular Surgery is a quarterly aimed at cardiologists, cardiosurgeons and thoracic surgeons. Includes the original works (experimental, research and development), illustrative and casuistical works about cardiology and cardiosurgery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信